- Home
- UROY vs SMTI Comparison
UROY vs SMTI Comparison
Compare UROY & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- SMTI
- Stock Information
- Founded
- UROY 2017
- SMTI 1982
- Country
- UROY Canada
- SMTI United States
- Employees
- UROY N/A
- SMTI N/A
- Industry
- UROY
- SMTI Medical/Dental Instruments
- Sector
- UROY
- SMTI Health Care
- Exchange
- UROY Nasdaq
- SMTI Nasdaq
- Market Cap
- UROY 351.1M
- SMTI 288.2M
- IPO Year
- UROY N/A
- SMTI N/A
- Fundamental
- Price
- UROY $2.71
- SMTI $35.02
- Analyst Decision
- UROY Strong Buy
- SMTI Buy
- Analyst Count
- UROY 2
- SMTI 1
- Target Price
- UROY $5.60
- SMTI $44.00
- AVG Volume (30 Days)
- UROY 2.3M
- SMTI 24.7K
- Earning Date
- UROY 12-11-2024
- SMTI 11-12-2024
- Dividend Yield
- UROY N/A
- SMTI N/A
- EPS Growth
- UROY N/A
- SMTI N/A
- EPS
- UROY 0.05
- SMTI N/A
- Revenue
- UROY $30,916,580.00
- SMTI $72,410,222.00
- Revenue This Year
- UROY N/A
- SMTI $26.97
- Revenue Next Year
- UROY $72.53
- SMTI $18.91
- P/E Ratio
- UROY $57.89
- SMTI N/A
- Revenue Growth
- UROY 208.26
- SMTI 21.42
- 52 Week Low
- UROY $1.86
- SMTI $26.00
- 52 Week High
- UROY $3.76
- SMTI $43.25
- Technical
- Relative Strength Index (RSI)
- UROY 55.91
- SMTI 64.02
- Support Level
- UROY $2.62
- SMTI $32.91
- Resistance Level
- UROY $2.96
- SMTI $34.03
- Average True Range (ATR)
- UROY 0.16
- SMTI 1.39
- MACD
- UROY -0.03
- SMTI 0.24
- Stochastic Oscillator
- UROY 47.37
- SMTI 100.00
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.